A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Ab Cellera Biologics Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 1,757,600 shares of ABCL stock, worth $5.2 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
1,757,600
Previous 993,300 76.95%
Holding current value
$5.2 Million
Previous $5.67 Million 40.38%
% of portfolio
0.02%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$4.29 - $5.97 $3.28 Million - $4.56 Million
764,300 Added 76.95%
1,757,600 $7.96 Million
Q4 2023

Feb 14, 2024

BUY
$3.91 - $5.93 $1.14 Million - $1.72 Million
290,400 Added 41.31%
993,300 $5.67 Million
Q3 2023

Nov 14, 2023

BUY
$4.6 - $7.95 $517,959 - $895,170
112,600 Added 19.08%
702,900 $3.23 Million
Q2 2023

Aug 14, 2023

BUY
$5.66 - $7.59 $282,434 - $378,741
49,900 Added 9.23%
590,300 $3.81 Million
Q1 2023

May 15, 2023

SELL
$7.31 - $11.18 $646,204 - $988,312
-88,400 Reduced 14.06%
540,400 $4.07 Million
Q4 2022

Feb 14, 2023

BUY
$9.48 - $14.52 $1.53 Million - $2.34 Million
161,100 Added 34.45%
628,800 $6.37 Million
Q3 2022

Nov 14, 2022

BUY
$9.2 - $13.68 $3.87 Million - $5.75 Million
420,400 Added 888.79%
467,700 $4.63 Million
Q3 2022

Nov 14, 2022

BUY
$9.2 - $13.68 $3.87 Million - $5.75 Million
420,400 Added 888.79%
467,700 $4.63 Million
Q2 2022

Aug 15, 2022

BUY
$5.72 - $10.65 $130,988 - $243,885
22,900 Added 93.85%
47,300 $504,000
Q1 2022

May 16, 2022

BUY
$7.46 - $14.14 $182,024 - $345,016
24,400 New
24,400 $238,000
Q2 2021

Aug 16, 2021

SELL
$20.19 - $34.17 $419,952 - $710,736
-20,800 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$23.29 - $53.2 $484,432 - $1.11 Million
20,800 New
20,800 $706,000

Others Institutions Holding ABCL

About AbCellera Biologics Inc.


  • Ticker ABCL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 285,139,008
  • Market Cap $844M
  • Description
  • AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in ...
More about ABCL
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.